OCA
EWTX icon

Octagon Capital Advisors’s Edgewise Therapeutics EWTX Stock Holding History

Octagon Capital Advisors’s Portfolio EWTX Stock Details EWTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-50,000
Closed -$830K – 31
2021
Q3 		$830K Sell
50,000
-75,000
-60% -$1.36M 0.2% 28
2021
Q2 		$2.67M Hold
125,000
– – 0.55% 34
2021
Q1 		$4.06M Buy
+125,000
New +$4.05M 1.53% 25

Other funds holding EWTX

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
NLVP
New Leaf Venture Partners New York $43M AUM 25.55% 1-Year Est. Return

Octagon Capital Advisors's EWTX Position: Q4 2021 in Review

Octagon Capital Advisors sold out of Edgewise Therapeutics (EWTX) in Q4 2021, closing a stake of 50,000 shares — an estimated $830K sold.

Octagon Capital Advisors first reported a position in EWTX in Q1 2021 and held it in 3 quarters. The position peaked at $4.06M in Q1 2021. 58 funds tracked by Wall St. Rank hold EWTX as of Q4 2021.

  • Octagon Capital Advisors reported no remaining Edgewise Therapeutics position as of Q4 2021 after selling out during the quarter.
  • Octagon Capital Advisors sold 50,000 Edgewise Therapeutics shares in Q4 2021, an estimated $830K.
  • Octagon Capital Advisors first reported a position in Edgewise Therapeutics in Q1 2021 and held it in 3 quarters.
  • Octagon Capital Advisors's Edgewise Therapeutics position peaked at $4.06M in Q1 2021.
  • 58 funds tracked by Wall St. Rank held Edgewise Therapeutics as of Q4 2021.

Based on Octagon Capital Advisors's 13F filing for Q4 2021, filed 14 Feb 2022.